Per- and polyfluoroalkyl substances and blood lipid levels in pre-diabetic adults—longitudinal analysis of the diabetes prevention program outcomes study
Exposure to per- and polyfluoroalkyl substances (PFASs) may interfere with lipid regulation. However, most previous studies were cross-sectional with the risk of reverse causation, suggesting a need for long-term prospective studies. We examined the relationship of baseline plasma PFAS concentration...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-08-01
|
Series: | Environment International |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0160412019305094 |
id |
doaj-4c8a90ad902d4046acbf59f5d51d6320 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Pi-I D. Lin Andres Cardenas Russ Hauser Diane R. Gold Ken P. Kleinman Marie-France Hivert Abby F. Fleisch Antonia M. Calafat Thomas F. Webster Edward S. Horton Emily Oken |
spellingShingle |
Pi-I D. Lin Andres Cardenas Russ Hauser Diane R. Gold Ken P. Kleinman Marie-France Hivert Abby F. Fleisch Antonia M. Calafat Thomas F. Webster Edward S. Horton Emily Oken Per- and polyfluoroalkyl substances and blood lipid levels in pre-diabetic adults—longitudinal analysis of the diabetes prevention program outcomes study Environment International |
author_facet |
Pi-I D. Lin Andres Cardenas Russ Hauser Diane R. Gold Ken P. Kleinman Marie-France Hivert Abby F. Fleisch Antonia M. Calafat Thomas F. Webster Edward S. Horton Emily Oken |
author_sort |
Pi-I D. Lin |
title |
Per- and polyfluoroalkyl substances and blood lipid levels in pre-diabetic adults—longitudinal analysis of the diabetes prevention program outcomes study |
title_short |
Per- and polyfluoroalkyl substances and blood lipid levels in pre-diabetic adults—longitudinal analysis of the diabetes prevention program outcomes study |
title_full |
Per- and polyfluoroalkyl substances and blood lipid levels in pre-diabetic adults—longitudinal analysis of the diabetes prevention program outcomes study |
title_fullStr |
Per- and polyfluoroalkyl substances and blood lipid levels in pre-diabetic adults—longitudinal analysis of the diabetes prevention program outcomes study |
title_full_unstemmed |
Per- and polyfluoroalkyl substances and blood lipid levels in pre-diabetic adults—longitudinal analysis of the diabetes prevention program outcomes study |
title_sort |
per- and polyfluoroalkyl substances and blood lipid levels in pre-diabetic adults—longitudinal analysis of the diabetes prevention program outcomes study |
publisher |
Elsevier |
series |
Environment International |
issn |
0160-4120 |
publishDate |
2019-08-01 |
description |
Exposure to per- and polyfluoroalkyl substances (PFASs) may interfere with lipid regulation. However, most previous studies were cross-sectional with the risk of reverse causation, suggesting a need for long-term prospective studies. We examined the relationship of baseline plasma PFAS concentrations with repeated measures of blood lipids. We included 888 prediabetic adults from the Diabetes Prevention Program (DPP) and DPP Outcomes Study, who had measurements of 6 plasma PFAS concentrations at baseline (1996–1999) and repeated measures of blood lipids over 15 years of follow-up, and were initially randomized to placebo or a lifestyle intervention. We used linear regression to examine cross-sectional associations of PFAS concentrations and lipid levels at baseline, and evaluated prospective risks of hypercholesterolemia and hypertriglyceridemia using Cox proportional hazard models, and tested for effect modification by study arm. Participants (65.9% female, 57.0% White, 65.9% aged 40–59 years) had comparable PFAS concentrations [e.g., median (IQR) perfluorooctanoic acid (PFOA) 4.9 ng/mL (3.2)] with the general U.S. population in 1999–2000. We observed higher total cholesterol at baseline per doubling of PFOA (β: 6.1 mg/dL, 95% CI: 3.1, 9.04), perfluorohexane sulfonic acid (PFHxS, β: 2.2 mg/dL, 95% CI: 0.2, 4.3), and perfluorononanoic acid (PFNA, β: 2.9 mg/dL, 95% CI: 0.7, 5.0). Prospectively, baseline concentrations of several PFASs, including PFOA, PFOS, PFHxS and PFNA, predicted higher risks of incident hypercholesterolemia and hypertriglyceridemia, but only in the placebo group and not the lifestyle intervention group. For example, participants in the placebo group with PFOA concentration > median (4.9 ng/mL) were almost twice as likely (HR: 1.90, 95% CI: 1.25, 2.88) to develop hypertriglyceridemia compared to those ≤median. Findings suggest adverse effects of some PFASs on lipid profiles in prediabetic adults. However, the detrimental effect was attenuated with a lifestyle intervention. Keywords: Lipid and cholesterol, Hyperlipidemia, Per- and polyfluoroalkyl substances, Environmental epidemiology, Lifestyle intervention, Prospective assessment |
url |
http://www.sciencedirect.com/science/article/pii/S0160412019305094 |
work_keys_str_mv |
AT piidlin perandpolyfluoroalkylsubstancesandbloodlipidlevelsinprediabeticadultslongitudinalanalysisofthediabetespreventionprogramoutcomesstudy AT andrescardenas perandpolyfluoroalkylsubstancesandbloodlipidlevelsinprediabeticadultslongitudinalanalysisofthediabetespreventionprogramoutcomesstudy AT russhauser perandpolyfluoroalkylsubstancesandbloodlipidlevelsinprediabeticadultslongitudinalanalysisofthediabetespreventionprogramoutcomesstudy AT dianergold perandpolyfluoroalkylsubstancesandbloodlipidlevelsinprediabeticadultslongitudinalanalysisofthediabetespreventionprogramoutcomesstudy AT kenpkleinman perandpolyfluoroalkylsubstancesandbloodlipidlevelsinprediabeticadultslongitudinalanalysisofthediabetespreventionprogramoutcomesstudy AT mariefrancehivert perandpolyfluoroalkylsubstancesandbloodlipidlevelsinprediabeticadultslongitudinalanalysisofthediabetespreventionprogramoutcomesstudy AT abbyffleisch perandpolyfluoroalkylsubstancesandbloodlipidlevelsinprediabeticadultslongitudinalanalysisofthediabetespreventionprogramoutcomesstudy AT antoniamcalafat perandpolyfluoroalkylsubstancesandbloodlipidlevelsinprediabeticadultslongitudinalanalysisofthediabetespreventionprogramoutcomesstudy AT thomasfwebster perandpolyfluoroalkylsubstancesandbloodlipidlevelsinprediabeticadultslongitudinalanalysisofthediabetespreventionprogramoutcomesstudy AT edwardshorton perandpolyfluoroalkylsubstancesandbloodlipidlevelsinprediabeticadultslongitudinalanalysisofthediabetespreventionprogramoutcomesstudy AT emilyoken perandpolyfluoroalkylsubstancesandbloodlipidlevelsinprediabeticadultslongitudinalanalysisofthediabetespreventionprogramoutcomesstudy |
_version_ |
1725131505287561216 |
spelling |
doaj-4c8a90ad902d4046acbf59f5d51d63202020-11-25T01:21:14ZengElsevierEnvironment International0160-41202019-08-01129343353Per- and polyfluoroalkyl substances and blood lipid levels in pre-diabetic adults—longitudinal analysis of the diabetes prevention program outcomes studyPi-I D. Lin0Andres Cardenas1Russ Hauser2Diane R. Gold3Ken P. Kleinman4Marie-France Hivert5Abby F. Fleisch6Antonia M. Calafat7Thomas F. Webster8Edward S. Horton9Emily Oken10Division of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USADivision of Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA, USADepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USADepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USADepartment of Biostatistics, School of Public Health and Human Sciences, University of Massachusetts Amherst, Amherst, MA, USADivision of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA; Diabetes Unit, Massachusetts General Hospital, Boston, MA, USAPediatric Endocrinology and Diabetes, Maine Medical Center, Portland, ME, USA; Center for Outcomes Research and Evaluation, Maine Medical Center Research Institute, Portland, ME, USADivision of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USADepartment of Environmental Health, Boston University School of Public Health, Boston, MA, USAJoslin Diabetes Center, Harvard Medical School, Boston, MA, USADivision of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA; Corresponding author at: Division of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, 401 Park Drive, Suite 401, Boston, MA 02215, USA.Exposure to per- and polyfluoroalkyl substances (PFASs) may interfere with lipid regulation. However, most previous studies were cross-sectional with the risk of reverse causation, suggesting a need for long-term prospective studies. We examined the relationship of baseline plasma PFAS concentrations with repeated measures of blood lipids. We included 888 prediabetic adults from the Diabetes Prevention Program (DPP) and DPP Outcomes Study, who had measurements of 6 plasma PFAS concentrations at baseline (1996–1999) and repeated measures of blood lipids over 15 years of follow-up, and were initially randomized to placebo or a lifestyle intervention. We used linear regression to examine cross-sectional associations of PFAS concentrations and lipid levels at baseline, and evaluated prospective risks of hypercholesterolemia and hypertriglyceridemia using Cox proportional hazard models, and tested for effect modification by study arm. Participants (65.9% female, 57.0% White, 65.9% aged 40–59 years) had comparable PFAS concentrations [e.g., median (IQR) perfluorooctanoic acid (PFOA) 4.9 ng/mL (3.2)] with the general U.S. population in 1999–2000. We observed higher total cholesterol at baseline per doubling of PFOA (β: 6.1 mg/dL, 95% CI: 3.1, 9.04), perfluorohexane sulfonic acid (PFHxS, β: 2.2 mg/dL, 95% CI: 0.2, 4.3), and perfluorononanoic acid (PFNA, β: 2.9 mg/dL, 95% CI: 0.7, 5.0). Prospectively, baseline concentrations of several PFASs, including PFOA, PFOS, PFHxS and PFNA, predicted higher risks of incident hypercholesterolemia and hypertriglyceridemia, but only in the placebo group and not the lifestyle intervention group. For example, participants in the placebo group with PFOA concentration > median (4.9 ng/mL) were almost twice as likely (HR: 1.90, 95% CI: 1.25, 2.88) to develop hypertriglyceridemia compared to those ≤median. Findings suggest adverse effects of some PFASs on lipid profiles in prediabetic adults. However, the detrimental effect was attenuated with a lifestyle intervention. Keywords: Lipid and cholesterol, Hyperlipidemia, Per- and polyfluoroalkyl substances, Environmental epidemiology, Lifestyle intervention, Prospective assessmenthttp://www.sciencedirect.com/science/article/pii/S0160412019305094 |